| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
EC50: NAMPT (3.29 μM)
JGB-1-155 targets nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD⁺ salvage pathway. As a positive allosteric modulator, it enhances NAMPT enzymatic activity with an EC50 of 3.29 μM. By increasing NAMPT activity, JGB-1-155 elevates intracellular NAD⁺ levels, which plays a critical role in cellular metabolism, redox balance, and inflammatory signaling. |
|---|---|
| ln Vitro |
In vitro studies demonstrate that JGB-1-155 is a positive allosteric modulator of NAMPT with an EC50 of 3.29 μM. It enhances NAMPT enzymatic activity and elevates intracellular NAD⁺ levels in human monocytes. The compound attenuates TNFα-induced reactive oxygen species production. These activities support its application in studies of redox balance and inflammatory signaling.
|
| ln Vivo |
In vivo activity of JGB-1-155 is inferred from its mechanism as a positive allosteric modulator of NAMPT that elevates NAD⁺ levels and attenuates oxidative stress. By enhancing NAMPT activity, the compound may have beneficial effects in conditions involving NAD⁺ depletion, oxidative stress, and inflammation. Detailed in vivo efficacy data from animal models are not extensively documented in the available literature. The compound is intended for research use only.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for JGB-1-155 involves measuring its ability to enhance NAMPT enzymatic activity. The assay typically uses purified recombinant NAMPT enzyme incubated with the compound at varying concentrations, along with substrates (nicotinamide and phosphoribosyl pyrophosphate). Enzyme activity is measured by quantifying the production of nicotinamide mononucleotide using methods such as HPLC or coupled enzymatic assays. The EC50 value of 3.29 μM is determined from the activation curve.
|
| Cell Assay |
In vitro cell-based assays for JGB-1-155 are conducted using human monocyte cell lines such as THP-1 cells. Cells are treated with the compound at various concentrations, and NAD⁺ levels are measured using biochemical assays. The compound's ability to attenuate TNFα-induced reactive oxygen species production is assessed using fluorescent probes. Cytotoxicity is evaluated using standard cell viability assays. Standard protocols include appropriate positive controls and vehicle controls.
|
| Animal Protocol |
In vivo animal studies for JGB-1-155 would typically be conducted using mouse models of oxidative stress, inflammation, or metabolic disorders. Animals would be administered the compound via appropriate routes, and NAD⁺ levels in tissues would be measured. Inflammatory markers and oxidative stress parameters would be assessed. However, detailed in vivo protocols and efficacy data are not available from the search results. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of JGB-1-155 are not extensively documented in the available literature. The compound has CAS number 3011930-28-9. Detailed pharmacokinetic parameters such as solubility, half-life, and bioavailability are not available from the search results. The compound is intended for research use only and is not for human therapeutic applications. Storage and handling should follow standard procedures for research compounds.
|
| Toxicity/Toxicokinetics |
Toxicity information for JGB-1-155 is limited. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
JGB-1-155 is a positive allosteric modulator of NAMPT with an EC50 of 3.29 μM. It elevates intracellular NAD⁺ levels in human monocytes and attenuates TNFα-induced reactive oxygen species production. It supports studies of redox balance and inflammatory signaling. It has CAS 3011930-28-9. It is intended for research use only.
|
| Molecular Formula |
C26H38N2O3
|
|---|---|
| Molecular Weight |
426.59
|
| CAS # |
3011930-28-9
|
| Appearance |
Oil
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3442 mL | 11.7209 mL | 23.4417 mL | |
| 5 mM | 0.4688 mL | 2.3442 mL | 4.6883 mL | |
| 10 mM | 0.2344 mL | 1.1721 mL | 2.3442 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
